Menu
Recruiting NCT06362928

Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary Embolism

No phase Interventional Pulmonary Embolism Acute

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: ATC System.
Who it may be relevant to
Registry conditions: Pulmonary Embolism Acute. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Austria
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study is a prospective, single-arm, non-randomized, interventional, multicenter feasibility study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).

Interventions

  • Device ATC System
    The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE

Primary outcome measures

  • Effectiveness [Time frame: 48 hours]
  • Safety: Composite of Major Adverse Device-Related Events [Time frame: 48 hours post index procedure]
Secondary outcome measures (1)
  • Safety: Composite of Major Adverse Events [Time frame: 30 days post index procedure]

Eligibility criteria

Inclusion criteria

  • Patient is > 18 and < 90 years old
  • Clinical signs and symptoms consistent with acute PE
  • PE symptom duration ≤ 14 days
  • CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery as determined by the investigator)
  • CTA evidence of RV/LV ratio > 0.9 note: based on Investigator's interpretation of RV/LV ratio at baseline;
  • Systolic BP ≥ 90 mmHg note: initial SBP may be < 90 mmHg but ≥ 80 mmHg if the pressure recovers with volume resuscitation
  • Stable heart rate (HR) < 130 BPM prior to procedure
  • Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment.
  • Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures

Exclusion criteria

  • Prior PE < 180 days from index procedure
  • Thrombolytic use < 48 hours prior to baseline CTA
  • Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) >70 mmHg by right heart catheterization
  • Vasopressor requirement after fluids to keep pressure at ≥90 mmHg
  • FiO2 requirement >40% or >6 LPM to keep oxygen saturation >90%
  • Hematocrit <28% (Note: hematocrit required within 6 hrs. of index procedure)
  • Platelets count <100,000/µL
  • eGFR <30 ml/min per 1.73 m2
  • International normalized ratio (INR) >3
  • Major trauma injury severity score (ISS) > 15
  • Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment
  • Cardiovascular or pulmonary surgery within 7 days of index procedure
  • Actively progressing cancer treated by chemotherapeutics
  • Known bleeding diathesis or coagulation disorder
  • Left bundle branch block
  • History of severe or chronic pulmonary arterial hypertension
  • History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
  • History of decompensated heart failure
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • History of heparin-induced thrombocytopenia (HIT)
  • Contraindication to systemic or therapeutic doses of anticoagulants
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and/or right ventricle).
  • CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
  • Life expectancy <90 days, as determined by investigator
  • Female who is pregnant or nursing
  • Current participation in another investigational drug or device treatment study Note: observational or registry studies may be permitted with Sponsor approval

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Austria · 1 center
  • Univ.-Klinikum LKH Graz — Graz

Identifiers

NCT: NCT06362928 · CP-60005

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗